Skip To Main Content
Justin Miller on Muck Rack

Justin Miller

Frisco
As seen in: Forbes, The Atlantic, Associated Press, The Globe and Mail, ACS Publications, Seeking Alpha, Popular Science, Benzinga, Royal Society of Chemistry, South Florida Sun Sentinel and
Justin is an experienced IT leader with a passion for improving every day. He enjoys huge challenges and is a driver for change.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Justin

Contact Justin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Shekinah Global Healthcare Foundation to Provide Free Surgery and Medical Care in Ibadan, Nigeria, September 20-26

|
By Justin Miller
| EIN Presswire
A Shekinah Global Volunteer Clinician comforts a patient during the January 2026 mission in Abeokuta, Nigeria. A Shekinah Global Volunteer Clinician examines a young child alongside the child's mother at the mission clinic. Dr. Adeboye alongside volunteer clinicians from the mission team on site in Nigeria. Volunteer Clinicians sort and dispense medication at the mission pharmacy station. Dr. Adeolu Adeboye, MD - founder and president, Shekinah Global Healthcare Foundation.
Open in Who Shared View Duplicates (236) Issue with article?

Gilead: Buy The Distortion Before Q2 Clears It Up

|
By Justin Miller
| Seeking Alpha
Summary Gilead Sciences is a buy, as a temporary $11.5 billion IPR&D charge distorts optics but not fundamentals. GILD's HIV franchise is growing 8% with patent protection through 2036 and up to seven new launches by 2033. Oncology inflection is underway, led by Trodelvy's first-line expansion and strategic acquisitions building a next-gen pipeline. At 14.5x normalized forward earnings, GILD trades at a 20–25% discount to peers despite superior margins and growth visibility.
Open in Who Shared Issue with article?

GSK: Buy The Discount Before The Catalysts Close It

|
By Justin Miller
| Seeking Alpha
Summary GSK (GSK) trades at a 42% discount to pharma peers, despite resilient earnings projections through the dolutegravir patent cliff. The HIV franchise's shift to long-acting injectables, protected by new IP, is driving 30–44% growth and mitigating generic risk. Nuvalent acquisition brings two near-term oncology launches, expected to improve margins and offset dolutegravir LOE impact.
Open in Who Shared Issue with article?
See all 90 licensed articles (92 Total)